Tilray Brands, Inc.

TLRY

US88688T1007

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1.75 ^USD	-4.89%		+1.74%	-23.91%

Apr. 24	Tilray Brands, Inc. Introduces New Signature 'Bud Squad' Products	CI
Apr. 23	TSX climbs as tech stocks power broader recovery	RE

Tilray, Inc. Appoints Jim Meiers as Chief Operations Officer

October 19, 2021 at 07:30 am EDT

Tilray, Inc. announced appointment of Jim Meiers as Chief Operations Officer.

Latest news about Tilray Brands, Inc.

Tilray Brands, Inc. Introduces New Signature 'Bud Squad' Products	Apr. 24	CI
TSX climbs as tech stocks power broader recovery	Apr. 23	RE
Tilray's Montauk Brewing Releases First Non-Alcoholic Brew	Apr. 11	MT
Social Buzz: Wallstreetbets Stocks Mostly Higher Premarket Wednesday; Tilray Brands to Advance, Trump Media & Technology Group to Decline	Apr. 10	MT
Piper Sandler On Tilray Brands; Guidance Bar Lowered, US Regulatory Outlook Unclear	Apr. 09	MT
TSX extends record-setting run as mining shares climb	Apr. 09	RE
TSX Produces a Total Eclipse of Its Own	Apr. 09	MT
Sector Update: Consumer Stocks Advance Late Afternoon	Apr. 09	MT
Top Midday Decliners	Apr. 09	MT
US Equity Indexes Slip, Gold Soars to Fresh Record Ahead of Consumer Price Index	Apr. 09	MT
Sector Update: Consumer Stocks Rise in Tuesday Afternoon Trading	Apr. 09	MT
Sector Update: Consumer	Apr. 09	MT
US Equity Indexes Decline While Gold Touches Fresh Record in Midday Trading	Apr. 09	MT
Toronto Stocks Advance; Tilray Brands Down on Outlook Cut, 3Q Misses	Apr. 09	DJ
TSX up 57 Points at Midday, With Miners, The Biggest Gainer; Healthcare Down 5.8%	Apr. 09	MT
Tilray Brands' Fiscal Third-Quarter Sales Miss Views; 2024 EBITDA Outlook Reduced	Apr. 09	MT
TSX pares gains after hitting record high on materials boost	Apr. 09	RE
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	Apr. 09	MT
Tilray's Fiscal Q3 Adjusted Earnings Down, Revenue Up; Fiscal 2024 Guidance Cut; Shares Fall Pre-Bell	Apr. 09	MT
Transcript : Tilray Brands, Inc., Q3 2024 Earnings Call, Apr 09, 2024	Apr. 09
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday on Caution Ahead of Inflation Data	Apr. 09	MT
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell	Apr. 09	MT
Tilray Brands Down 12% In US Premarket Although Q3 2024 Net Loss Narrows and Net Revs Rise; But Updated FY24 Guidance	Apr. 09	MT
Tilray's Fiscal Q3 Earnings Down, Revenue Up; Shares Fall Pre-Bell	Apr. 09	MT
Tilray Brief: In addition, Company no longer expects to generate positive adjusted free cash flow for the full fiscal year 2024, due to delayed timing for collecting cash on various asset sales	Apr. 09	MT

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis business, Distribution business, Beverage alcohol business and Wellness business. The Cannabis business segment is engaged in the production, distribution, sale, co-manufacturing, and advisory services of both medical and adult-use cannabis. The Distribution business segment is focused on the purchase and resale of pharmaceutical products to customers. The Beverage alcohol business segment is engaged in the production, marketing and sale of beverage and beverage alcohol products. The Wellness business segment includes hemp foods and hemp-based cannabidiol (CBD) consumer products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Bake Sale, XMG, Mollo, and others.

Sector

Pharmaceuticals

Calendar

2024-07-23 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

US Consumer Confused About Pot Rules, Tilray CEO Says

October 17, 2023 at 02:38 pm EDT

More Strategies

Ratings for Tilray Brands, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.75 USD

Average target price

2.375 USD

Spread / Average Target

+35.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TILRAY BRANDS, INC.	-23.91%	1.42B
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.33%	358B
MERCK & CO., INC.	+19.90%	322B
ABBVIE INC.	+7.95%	297B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-12.26%	149B
AMGEN INC.	-6.47%	146B

Other Pharmaceuticals

Tilray Brands, Inc.

Equities

TLRY

US88688T1007

Pharmaceuticals

Tilray, Inc. Appoints Jim Meiers as Chief Operations Officer

Latest news about Tilray Brands, Inc.

Chart Tilray Brands, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Tilray Brands, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals